- Trials with a EudraCT protocol (203)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
203 result(s) found for: ER+ PR+ HER2- Breast Cancer.
Displaying page 1 of 11.
EudraCT Number: 2006-002766-20 | Sponsor Protocol Number: CAUY922A2101 | Start Date*: 2009-02-25 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in... | ||
Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003581-41 | Sponsor Protocol Number: J2J-MC-JZLA | Start Date*: 2020-09-08 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select ... | ||
Medical condition: ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006430-10 | Sponsor Protocol Number: CTKI258A2202 | Start Date*: 2009-06-22 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. | |||||||||||||
Medical condition: In female patients with FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002192-18 | Sponsor Protocol Number: TRIO020 | Start Date*: 2013-10-17 |
Sponsor Name:Translational Research In Oncology | ||
Full Title: A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression | ||
Medical condition: Advanced ER+, HER2- postmenopausal breast cancer with low ER expression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004470-26 | Sponsor Protocol Number: ICR-CTSU/2006/10003 | Start Date*: 2007-07-05 | |||||||||||
Sponsor Name:The Institute of Cancer Research [...] | |||||||||||||
Full Title: Triple Negative breast cancer Trial. A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- breast cancer | |||||||||||||
Medical condition: metastatic or recurrent locally advanced breast cancer that is ER-, PR- (or unknown) and HER2- or known BRCA1/BRCA 2 carriers. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002113-39 | Sponsor Protocol Number: BAY88-8223/16298 | Start Date*: 2014-10-29 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ... | |||||||||||||
Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003220-52 | Sponsor Protocol Number: CC-486-BRSTM-001 | Start Date*: 2015-03-21 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Postmenopausal female subjects with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer, who have progressed on an aromatase inhibi... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000954-86 | Sponsor Protocol Number: 107CS-5 | Start Date*: 2020-08-17 | ||||||||||||||||
Sponsor Name:Daehwa Pharmaceutical Co., Ltd. | ||||||||||||||||||
Full Title: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients wit... | ||||||||||||||||||
Medical condition: Recurrent or metastatic HER2 negative Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Ongoing) BG (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000106-19 | Sponsor Protocol Number: GO29689 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Genentech, Inc | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY | |||||||||||||
Medical condition: Advanced or Metastatic ER+/HER2- Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005181-30 | Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 | Start Date*: 2015-07-09 | |||||||||||
Sponsor Name:ABCSG GmbH | |||||||||||||
Full Title: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor... | |||||||||||||
Medical condition: To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) ES (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) DE (Ongoing) SE (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003187-44 | Sponsor Protocol Number: UC-0140/1208 | Start Date*: 2012-09-25 |
Sponsor Name:UNICANCER | ||
Full Title: Randomized, double-blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast ... | ||
Medical condition: women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease after receiving 3 years of adjuvant hormone therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Ongoing) BE (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002525-29 | Sponsor Protocol Number: UC-0140/1206 | Start Date*: 2013-03-08 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer. | |||||||||||||
Medical condition: Molecular apocrine locally advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001824-33 | Sponsor Protocol Number: EFC15935 | Start Date*: 2020-10-19 | ||||||||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | ||||||||||||||||||
Full Title: A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not ... | ||||||||||||||||||
Medical condition: ER (+), HER2 (-) breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) FI (Completed) CZ (Completed) AT (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004190-13 | Sponsor Protocol Number: TX05-03 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:Tanvex Biologics Corp. | |||||||||||||
Full Title: A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer | |||||||||||||
Medical condition: HER-2 positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020395-28 | Sponsor Protocol Number: ARD11588(MM-121-02-02-03) | Start Date*: 2011-04-14 | |||||||||||
Sponsor Name:MERRIMACK PHARMACEUTICALS | |||||||||||||
Full Title: Estudio de fase II, aleatorizado, doble ciego de exemestano +/- MM-121 en mujeres posmenopáusicas con cáncer de mama Her2 negativo localmente avanzado o metastásico, con receptores de estrógeno pos... | |||||||||||||
Medical condition: cáncer de mama_____Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005209-23 | Sponsor Protocol Number: CA163139 | Start Date*: 2008-03-21 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/... | |||||||||||||
Medical condition: BREAST CANCER, FIRST LINE | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005000-13 | Sponsor Protocol Number: EMR200027-051 | Start Date*: 2007-03-30 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: Randomized Phase II trial with cetuximab and cisplatin in the treatment of ER negative, PgR negative, HER2 negative metastatic breast carcinoma (“basal-like”) | |||||||||||||
Medical condition: Metastatic breast cancer PR-negative, ER-negative and HER-2 negative | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) ES (Completed) AT (Completed) PT (Completed) DE (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002114-23 | Sponsor Protocol Number: BAY88-8223/17096 | Start Date*: 2015-10-26 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe... | |||||||||||||
Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004010-28 | Sponsor Protocol Number: I3Y-MC-JPBO | Start Date*: 2015-03-10 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma | |||||||||||||
Medical condition: Brain tumors, Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000419-17 | Sponsor Protocol Number: AFT-38 | Start Date*: 2017-08-25 | |||||||||||||||||||||
Sponsor Name:Alliance Foundation Trials, LLC | |||||||||||||||||||||||
Full Title: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatm... | |||||||||||||||||||||||
Medical condition: HER2 Positive Breast Cancer Estrogen Receptor Positive Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) FR (Ongoing) PT (Ongoing) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.